Quality control material for the detection of somatic mutations in fixed clinical specimens by next-generation sequencing.
Diagnostic Pathology, January 2015
Catherine I Dumur, Jorge A Almenara, Celeste N Powers, Andrea Ferreira-Gonzalez
Targeted next generation sequencing (NGS) technology to assess the mutational status of multiple genes on formalin-fixed, paraffin embedded (FFPE) tumors is rapidly being adopted in clinical settings, where quality control (QC) practices are required. Establishing reliable FFPE QC materials for NGS can be challenging and/or expensive. Here, we established a reliable and cost-effective FFPE QC material for routine utilization in the Ion AmpliSeq™ Cancer Hotspot Panel v2 (CHP2) assay. The performance characteristics of the CHP2 assay were determined by sequencing various cell line mixtures and 55 different FFPE tumors on the Ion Torrent PGM platform. A FFPE QC material was prepared from a mixture of cell lines derived from different cancers, comprising single nucleotide variants and small deletions on actionable genes at different allelic frequencies. The CHP2 assay performed with high precision and sensitivity when custom variant calling pipeline parameters where established. In addition, all expected somatic variants in the QC material were consistently called at variant frequencies ranging from 9.1 % (CV = 11.1 %) to 37.9 % (CV = 2.8 %). The availability of a reliable and cost-effective QC material is instrumental in assessing the performance of this or any targeted NGS assay that detects somatic variants in fixed solid tumor specimens.
|Members of the public||1||33%|
|Readers by professional status||Count||As %|
|Student > Postgraduate||4||12%|
|Student > Ph. D. Student||4||12%|
|Student > Bachelor||3||9%|
|Student > Doctoral Student||2||6%|
|Readers by discipline||Count||As %|
|Biochemistry, Genetics and Molecular Biology||9||26%|
|Agricultural and Biological Sciences||9||26%|
|Medicine and Dentistry||4||12%|